Popularity #4,027Earnings are out
Tiziana Life Sciences (ADR) (TLSA)
Develops intranasal anti-CD3 immunotherapy for neuroinflammatory and neurodegenerative diseases.
$1.03
vs last close+0.14 (+15.18%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 3.81% | 2.42M ADS | |
|---|---|---|---|
| 33 holders · as of Jun 30, 2026 | |||
| Insiders | 91.87% | 58.45M ADS | |
| 6 holders · as of Aug 7, 2026 | |||
| Other | 4.32% | 2.75M ADS | |
| remainder | |||
63.63M ADS (1 ADS = 2 ordinary shares) as of Sep 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
13F, as of Jun 30, 2026
33 holders · 2.42M shares · 7 new positions · 16 increased · 4 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 1.16M | 1.83% | −1.00M | Aug 13, 2026 |
| Mid-American Wealth Advisory Group, Inc. | 323.2K | 0.51% | +323.2Knew | Jul 16, 2026 |
| Zhang Financial LLC | 126.0K | 0.20% | +14.1K | Jul 30, 2026 |
| Goldman Sachs Group Inc | 119.2K | 0.19% | +43.6K | Aug 14, 2026 |
| Citadel Advisors LLC | 80.2K | 0.13% | +45.1K | Sep 2, 2026 |
| Colony Group, LLC | 79.4K | 0.12% | 0 | Aug 12, 2026 |
| Geode Capital Management, LLC | 78.2K | 0.12% | 0 | Aug 12, 2026 |
| UBS Group AG | 72.9K | 0.11% | −22.8K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Laura Natalia Monica Fonda | 5.70% | 6.81M | 13G | Oct 28, 2025 |
| Chernett Jorey | 5.40% | 6.48M | 13G | Dec 10, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 12, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 15,000 | $1.11 | 44,772,230 |
| Jul 21, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 42,357 | $0.9900 | 44,814,587 |
| Aug 4, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 83,807 | $0.9700 | 4,556,068 |
| Aug 5, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 237,616 | $1.00 | 4,793,684 |
| Aug 3, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 667,000 | $1.00 | 4,472,261 |
House and Senate disclosures
Not reported.